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Bladder exstrophy is a rare birth defect that typically requires patients to undergo multiple surgical
procedures throughout the course of their childhood. Many ultimately undergo operations that use
segments of bowel for the reconstruction and/or augmentation of the urinary tract, which imparts an
increased risk of malignancy in these patients. We present the case of a 59-year-old manwith a history of
bladder exstrophy managed with ureterosigmoidostomies revised to an ileal conduit who developed a
large adenocarcinoma in the ileal conduit that extended into small bowel, sigmoid colon, and ureter.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Bladder exstrophy is a rare birth defect that typically requires
multiple operations using bowel segments for urinary tract
reconstruction and/or augmentation. When bowel is incorporated
into the urinary tract, the risk of neoplasia increases1; thus adult
patients with a history of bladder exstrophy require close surveil-
lance for potential malignancies.
In the following presentation of a 59-year-old man born with
bladder exstrophy, a large adenocarcinoma involving small bowel,
sigmoid colon, and ureter developed in an ileal conduit revised
from ureterosigmoidostomies.
Case presentation
A 59-year-old man with classic bladder exstrophy presented
with abdominal pain. Prior to 10 years of age, he underwent
bilateral ureterosigmoidostomies, which were revised to an ileal
conduit at age 18 when an 8-cm benign adenomatous sigmoid
colon polyp necessitated sigmoid colectomy. He required multipleþ410-955-0833.
Inc. Open access under CC BY-NC-NDileal conduit revisions. Most recently, an additional segment of
ileum was used to “patch” the distal aspect of the existing ileal
conduit at age 44. His last surveillance colonoscopy, performed the
year before presentation, demonstrated no suspicious lesions.
The patient had a history of recurrent left lower quadrant pain
and abdominal fullness managed with nil per os and antibiotics.
When such an episode did not resolve with this regimen, a non-
contrast computed tomographic (CT) scan of the abdomen and
pelvis revealed left hydroureteronephrosis to the level of the
conduit with renal parenchymal thinning and a soft tissue density
in the conduit. Dynamic nuclear renal imaging with Tc99m-
mercaptoacetyltriglycine (MAG3) and lasix conﬁrmed left ureteral
high-grade obstruction and 93% and 7% split function of the right
and left kidneys, respectively. On immediate transfer to the authors’
institution for further management, CT scan conﬁrmed severe left
hydronephrosis and an inﬁltrating 4-cm soft tissue mass in the
region of the ureteroenteric anastomosis of the ileal conduit, most
prominent on the left side, involving adjacent small bowel loops
and partially encasing the left iliac artery, that was not appreciated
on CT scan 1 year before.
Serum creatinine was elevated to 2.2 mg/dL (baseline 0.9 mg/
dL). A retrograde ureteral stent could not be placed, so a right-sided
percutaneous nephrostomy tube was inserted, eliciting a decrease
in serum creatinine to 1.4-1.6 mg/dL. At endoscopic evaluation, a
large mass visualized in the ileal conduit was biopsied. Pathology
demonstrated mild ﬁbrosis and chronic inﬂammation but no evi-
dence of tumor. Colonoscopy revealed no suspicious lesions. license.
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inﬁltrative 15-cm tumor in the proximal ileal conduit was seen
directly extending into the left ureter, sigmoid colon, descending
colon, several loops of small bowel, and small bowel mesentery. It
was situated over the aortic bifurcation, overlying both iliac ar-
teries. A retroperitoneal lymph node dissection, extensive enter-
olysis, and subtotal omentectomy were performed. The mass was
removed en bloc; the specimen included the left kidney, ureter, ileal
conduit, sigmoid colon, and small bowel. The entire ileal conduit
was resected. The right ureter was free of tumor, and a new ileal
conduit was created with remaining terminal ileum. Colo-
proctostomy and enteroenterostomy were performed after large
and small bowel resection, respectively.
Final pathology revealed a 6.2-cm moderately differentiated
adenocarcinoma arising in the ileal conduit with mucinous features
and angiolymphatic and perineural invasion. The tumor inﬁltrated
through the ileal conduit muscularis propria into underlying fat and
adjacent organs, including small bowel, sigmoid colon, and left
ureter. Left iliac periarterial tissue contained adenocarcinoma with
a positive surgical margin. One pericolonic lymph node of 69 total
lymph nodes contained metastatic adenocarcinoma.
At 2 months, the patient was doing well with a stable creatinine
and no evidence of disease on CT scan.
Discussion
Carcinogenesis in urinary diversions incorporating bowel is well
recognized in the medical published data. After ureter-
osigmoidostomy, the incidence of carcinoma is 2%-15%. This
translates into a 500-fold increase in colon cancer incidence when
compared with the general population. The average time between
ureterosigmoidostomy and cancer diagnosis is 20-26 years. How-
ever, patients with bladder exstrophy can develop adenocarcinoma
within just 10 years of urinary diversion.2 Prolonged exposure of
colonic mucosa to urine is believed to contribute to cancer risk after
ureterosigmoidostomy. Although the exact mechanism has not
been elucidated, many theories involve the interaction among
urine, stool, intestinal mucosa, and the healing anastomosis.3 In
screening colonoscopies after ureterosigmoidostomy, the presence
of precursor lesions (dysplasia and adenomas) suggests an
adenoma-adenocarcinoma sequence characteristic of colorectal
cancer.4 Urinary conduits display histologic signs of chronic
inﬂammation after chronic exposure to urine. Substances released
by inﬂammatory cells may promote carcinogenesis, contributing to
the development of dysplasia and eventual malignancy1.
This patient had ureterosigmoidostomies for approximately 15
years until a benign polyp prompted sigmoid colectomy and crea-
tion of ileal conduit. Theoretically, sigmoid colectomy decreased themalignancy risk conferred at the time of ureterosigmoidostomy.
However, sigmoid colon and/or the ureterosigmoidostomy anas-
tomoses may not have been completely resected. A case report of a
patient with ureterosigmoidostomies revised to an ileal conduit
after 8 months who developed poorly differentiated sigmoid colon
adenocarcinoma at 36 years has been reported.5
In this case, the mass arose from the ileal conduit. In 2013, only
8810 new small bowel cancers have been estimated in the general
population, in contrast to 102,480 for colon cancer.6 It appears,
however, that chronic exposure of intestinal mucosa to urine in
urinary diversions and bladder augmentation increases this risk.1
Although strict guidelines for surveillance are not established,
urologists advocate initiating yearly screening 10-20 years after
incorporating bowel into the urinary tract. Some demonstrated that
screening is not required for at least 15 years after augmentation or
replacement cystoplasty.7 Owing to high malignancy risk after
ureterosigmoidostomy, initiating yearly sigmoidoscopy after 10
years is recommended.8 This patient had a CT scan and colonoscopy
the year before presentation, which showed negative ﬁndings. At
diagnosis, colonoscopy again showed negative ﬁndings, but
endoscopy of the ileal conduit revealed tumor. His last endoscopic
evaluation was approximately 4 years before presentation; there-
fore, yearly endoscopy of the ileal conduit may have prompted
earlier diagnosis.
Conclusion
This case highlights the importance of frequent screening in
patients with major congenital urologic defects and urinary tract
reconstruction and the importance of examining the entire recon-
structed urinary tract during screening.
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